Unlike in breast and gastric cancer, HER2 overexpression is not validated to be a biomarker predictive of clinical response to HER2-targeted agents in NSCLC. Similar to epidermal growth factor receptor (EGFR) mutations, the incidence of HER2 mutations is significantly increased in nonsmokers and women, as well as persons of Asian descent and those with adenocarcinoma NSCLCs.
Learn more about NSCLC.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.